BML Capital Management LLC boosted its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 61.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,261,559 shares of the biotechnology company's stock after acquiring an additional 480,267 shares during the quarter. Oramed Pharmaceuticals accounts for 2.2% of BML Capital Management LLC's holdings, making the stock its 11th largest holding. BML Capital Management LLC owned 3.13% of Oramed Pharmaceuticals worth $2,914,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Barclays PLC grew its stake in shares of Oramed Pharmaceuticals by 39.0% during the third quarter. Barclays PLC now owns 18,406 shares of the biotechnology company's stock worth $47,000 after buying an additional 5,167 shares during the last quarter. N.E.W. Advisory Services LLC bought a new stake in shares of Oramed Pharmaceuticals in the third quarter worth $34,000. Algert Global LLC bought a new stake in shares of Oramed Pharmaceuticals in the third quarter worth $38,000. Finally, Rathbones Group PLC bought a new stake in shares of Oramed Pharmaceuticals in the third quarter worth $756,000. Institutional investors own 12.73% of the company's stock.
Oramed Pharmaceuticals Price Performance
Shares of Oramed Pharmaceuticals stock traded up $0.02 during trading on Wednesday, hitting $2.37. The company's stock had a trading volume of 40,834 shares, compared to its average volume of 166,502. Oramed Pharmaceuticals Inc. has a 52 week low of $1.67 and a 52 week high of $5.25. The stock has a market cap of $96.03 million, a price-to-earnings ratio of 16.93 and a beta of 1.81. The stock has a 50-day moving average price of $2.86 and a two-hundred day moving average price of $2.47.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.04. On average, equities analysts predict that Oramed Pharmaceuticals Inc. will post -0.26 EPS for the current fiscal year.
Oramed Pharmaceuticals Company Profile
(
Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Further Reading
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
